A Randomized, Open Label, Single Dose, Crossover Study to Evaluate the Safety and Pharmacokinetic Characteristics After Administration of AD-102 in Healthy Male Subjects
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Colecalciferol/raloxifene (Primary)
- Indications Osteoporosis
- Focus Pharmacokinetics
- Sponsors Addpharma
- 29 Aug 2019 Status changed from not yet recruiting to completed.
- 08 Feb 2019 New trial record